Porter's Must-See, Urgent Market Briefing

The details of a historic market 'anomaly'... Porter sits down with Joel Litman... 'The most valuable information you'll ever get for free'... More from Dave Lashmet... How to bet on developmental drugs... Two tricks and a new pick... [Stansberry Research Logo] Delivering World-Class Financial Research Since 1999 [Stansberry Digest] The details of a historic market 'anomaly'... Porter sits down with Joel Litman... 'The most valuable information you'll ever get for free'... More from Dave Lashmet... How to bet on developmental drugs... Two tricks and a new pick... --------------------------------------------------------------- This morning, our founder Porter Stansberry let the secret out... In a must-see event that went live this morning, Porter sat down on camera with our friend Joel Litman, founder of our corporate affiliate Altimetry. They revealed what they agree is a massive financial story – and opportunity – that most people will never hear about. It's a historic "anomaly" that you don't see in the markets all that often. It's significant and potentially lucrative enough that Porter decided to team up with Joel, who has also been tracking it, to get the word out to individual investors before this opportunity slips away. Today, they did just that in a totally free presentation... In the presentation, Porter and Joel explained how this anomaly has emerged in a select group of stocks, and why it could lead to unparalleled returns... and soon. They explained all the details, like... - The institution that created this rare setup. (It's one we've talked about frequently.) - Why certain stocks tied to this story have jumped 170% in a single trading day... 100% in just a month... and 275% in about two weeks recently... - Where specifically to put money to take advantage of this anomaly... - The dangerous misconception people have about the stock market. - Why this could be the most important investing story of the year... or years... and why Porter wanted to speak specifically with Joel about it. There's plenty more, but I (Corey McLaughlin) urge you to watch for yourself... This has nothing to do with the "Magnificent Seven" or the presidential election... and doesn't involve trading options or bitcoin. Yet it could create enormous wealth for those who position themselves correctly. As Porter explains during the broadcast... If you understand what is happening today... if you understand why it is happening... and if you have the courage to take advantage of it... it could be the only investing story you need to pay attention to, ever again. When you add it all up, the message is the "most valuable information you'll ever get for free in your life," Porter said. [Click here to check out the entire presentation](. Again, it's free. And stay tuned... We'll look to share more information about this story in the days ahead. Now, switching gears, here's insight from our Dave Lashmet... As we explained yesterday, our colleague and Stansberry Venture Technology editor Dave Lashmet has been covering today's suddenly popular weight-loss drugs for years... long before they won approval from the U.S. Food and Drug Administration ("FDA") or entered the popular consciousness. And, recently, Dave and one of our colleagues at Stansberry Research, who has tried one of these drugs, have been sharing why they believe they represent a medical breakthrough... presenting one of the bigger investment opportunities of the next decade. To close out today's edition, Dave is back with more great insight on how he goes about distinguishing the winners from the losers in developmental drugs... He's pulling back the curtain... and shows how his strategy led to a brand-new recommendation for his Venture Technology subscribers, published just today. What you need to know about investing in developmental drugs... Like I (Dave Lashmet) [wrote yesterday]( investing in drugs in development is a rough business: 94% of drug candidates fail in clinical trials and never get FDA approval – and the rare success can take up to a decade to play out. Yes, any drug can succeed, but to make a successful investment, you have to distinguish between the one winner and 19 likely losers. How best to do that? We have two battle-proven strategies to cut through the inherent risk of drug development. Today, I'll explain... For starters, you should know that the world's largest pharma firms reduce their risks and costs by, for example, cutting their internal research teams in half and letting small outside firms develop the other half of their products. So, there is a lively business for venture capitalists and for retail investors to help support a promising drug at a small company. And their best hope for a payoff is a Big Pharma deal. Today, Big Pharma can step in to invest at any phase of development: early (Phase I), when only a few patients have tried out the new drug... mid-stage (Phase II), when dozens of folks have been treated... or later, following successful Phase III trials with hundreds of volunteers. There are arguments for investing at any stage, but my first trick has to do with what I think is the best one... Trick No. 1: Invest in FDA-approved drugs... This one should seem easy, or maybe sounds too simple... If a drug is already through its clinical development and has gained FDA approval, then you've eliminated its trial failure risk. But here's the thing: It still doesn't mean a drug will make money... An approved drug is like any product for sale, although given the price point for drugs these days, they are more like Swiss watches than bubble gum. We're talking up to tens of thousands of dollars, per patient, per year. So, a drug that can serve 100,000 people could be worth $500 million per year. In fact, that's the sweet spot that a Big Pharma company will look for in potential annual sales to put up the capital at risk to develop a drug. The floor is usually around $100 million per year. At $1 billion per year in sales, you have a blockbuster. Beyond that, there are a few classes of drugs that have blown right through the old standard and generated $10 billion or even $20 billion of sales after FDA approval. (Again, that's with developmental risks gone – so there's no 94% drop-out rate.) One class of drugs that did this is cancer immunotherapy drugs, and we saw this tidal wave coming... What it can look like... A decade ago, I went to the American Society of Clinical Oncology's annual cancer meetings as these drugs were completing their trials. Today, they generate tens of billions of dollars in revenue. But here's another critical element you should know in this space: Their patents – or exclusive use of these drugs – are getting closer to expiring... Drug patents last 20 years. For investors, putting money to work in companies making these drugs would be chasing the tail end of the trend. That's not what we want to do... It's far better to find drugs with blockbuster potential and invest in them while they are still ramping up, like the weight-loss drugs I've been writing about lately (and following for years). Here's what I mean... Here are the financials related to these drugs for the two major companies selling them today... One key takeaway is that these two companies' weight-loss drugs already brought in $28 billion last year. More important, revenues nearly doubled in just three fiscal quarters. That's some growth. Most people look at year-over-year figures, though, since this controls against seasonal changes. By this metric, the top weight-loss drugs are up 132% year over year. Ridiculous. Of course, all investing is aimed at the future. So the open question is, what happens next? As we shared last week, these companies can't even make these drugs fast enough to keep up with demand, meaning more growth potential ahead. Long story short for investors, this trend has not peaked... We think the top two companies will sell more of these drugs for as long as their patents (and commercial monopolies) last. You can hear more about these companies, plus learn more about my strategies and how to access my full research in Stansberry Venture Technology [here](. Overall, we've been tracking this sector for a decade, and these particular drugs since 2019. And I can assure you, early investors have liked riding this trend as it has grown huge. But this isn't the only way to make massive returns by investing in developmental drugs. You see, I recently uncovered a startling opportunity in this same market – an opportunity I sent to subscribers of Stansberry Venture Technology just today. And it has to do with my second strategy... Trick No. 2: Find what Big Pharma wants to buy – before they do... Flat out, this second strategy has more risk – because it requires you to invest before a drug is FDA-approved. So there's a chance this opportunity collapses completely. Remember, 94% of drugs in development fail to gain approval. But this strategy can also lead to bigger rewards... To gauge the potential winners from all the losers, one thing we look for is early indications that a drug seems safe and effective. It's not until the final trials are complete that we can be sure of this, but there are always signs. Another thing we look for is massive market potential: that a drug treats a dangerous condition that many folks have. Simply put, the more folks who need it, the more it's worth. But the last thing we look for is most important of all: the competitive landscape for this new drug, if it makes it through trials. What obstacles from other drug firms will it face? I can assure you, Big Pharma companies are great at dragging their rivals through the dust. And no small firm ever points out to its investors that it's going to face gigantic competitors. But this is reality... A case study in 'competitive landscape'... For example, let's look at the competitive landscape for this new drug that I wrote about to my subscribers today. Note that it's in the weight-loss-drug space that's growing at 132% per year... This landscape includes the weight-loss drugs we all know about – even Oprah pitched them [last week](. This includes the glucagon-like peptide-1 (GLP-1) class of drugs that we've talked about in these pages over the past few weeks. I have explained that these "gen 2" weight-loss drugs both raise your resting heart rate – so you burn more calories – plus they reduce your appetite. Together, that's how you lose weight. Technically, these meds work both in your brain and in your gut, so I've nicknamed them "winter switch" drugs – they make you run warmer, and not gobble up your stored harvest. A handful have FDA approval, and many more are still in various phases of clinical trials. But there is another "switch" in the body – which literally turns your hunger on or off, not just reduces appetite – that can be controlled and used to address weight loss, too. As an injectable drug, it is already FDA-approved and for sale. But what's exciting is a new once-daily pill in development that hits what I call your "hunger switch." You don't have to imagine what this is worth: I'll tell you, it's a lot. But only if the drug makes it through trials... For investors, the key takeaway is that this new pill has no competition. It won't fight the GLP-1 drugs that have quickly become popular, or anything else. The company's only competition is itself... That means Big Pharma firms have a choice... They can develop a 47th drug to try to hit your "winter switch," and end up with one in 10 years to try to win market share... Or they can buy a developmental drug with no competition. There are risks. But the reward is stratospheric. And if you're the company with the drug, and Big Pharma wants what you own, you just sell it. For my subscribers in Stansberry Venture Technology, I'm always looking for these kinds of opportunities, which can offer outsized returns. Specifically, I look for investments with what I consider a 10-to-1 reward-to-risk ratio, based on what our research shows about the science and market landscape. The recommendation I sent to Venture Technology subscribers today qualifies... It's a company working on a weight-loss pill – with no competition... that has not yet received FDA approval. It comes with risk but also the potential for big rewards. To learn more, including how you can get access to my new pick, the entire Venture Technology portfolio – and more information about the weight-loss-drug giants, too – [click here]( for a special message from our publisher, Brett Aitken. He'll tell you more about the opportunity in the weight-loss-drug space – "one of the biggest investing stories on Earth," he says – my background and work at Stansberry Research, and a special offer to subscribe to Venture Technology today. --------------------------------------------------------------- Recommended Links: # [NOW AIRING: 'The Most Valuable Information You Will Ever Get for Free in Your Life']( Stansberry Research founder Porter Stansberry famously predicted the fall of the iconic General Motors... and the rise of bitcoin around $10,000, before it soared past $60,000. Yet even still, he says the story he's breaking today is "without a doubt" the most valuable information you will ever get for free. [Click here to tune in now](. --------------------------------------------------------------- # [Bitcoin Dollar Warning]( There's a strange new situation unfolding behind the scenes in the U.S. banking system. It's connected to bitcoin and other leading cryptos... but it could have much wider implications for the U.S. dollar and American banking system. The Federal Reserve, U.S. Treasury, and 41 major banks are all involved – and plotting radical changes for America's money system. [Here's the full story](. --------------------------------------------------------------- New 52-week highs (as of 3/25/24): American Financial (AFG), Amazon (AMZN), Disney (DIS), Enerplus (ERF), iShares MSCI Spain Fund (EWP), Diamondback Energy (FANG), iShares Convertible Bond Fund (ICVT), iShares U.S. Aerospace & Defense Fund (ITA), MSA Safety (MSA), Micron Technology (MU), Pioneer Natural Resources (PXD), Ferrari (RACE), Construction Partners (ROAD), Stellantis (STLA), Tenaris (TS), and W.R. Berkley (WRB). In today's mail, just a quick PSA... We've noticed several subscribers asking where they can access various special reports that are part of a subscription to our newsletters. For starters, be sure you're signed into StansberryResearch.com, then navigate to the publication you're looking for and click the "View All Special Reports" link, like [here for Stansberry Innovations Report]( for example. Hope that helps... As always, e-mail your questions and comments to feedback@stansberryresearch.com. All the best, Corey McLaughlin with Dave Lashmet Baltimore, Maryland and Seattle, Washington March 26, 2024 --------------------------------------------------------------- Stansberry Research Top 10 Open Recommendations Top 10 highest-returning open positions across all Stansberry Research portfolios Stock Buy Date Return Publication Analyst MSFT Microsoft 11/11/10 1,376.9% Retirement Millionaire Doc MSFT Microsoft 02/10/12 1,343.7% Stansberry's Investment Advisory Porter wstETH Wrapped Staked Ethereum 02/21/20 1,173.5% Stansberry Innovations Report Wade ADP Automatic Data Processing 10/09/08 886.9% Extreme Value Ferris WRB W.R. Berkley 03/16/12 792.7% Stansberry's Investment Advisory Porter BTC/USD Bitcoin 01/16/20 628.7% Stansberry Innovations Report Wade BRK.B Berkshire Hathaway 04/01/09 626.8% Retirement Millionaire Doc HSY Hershey 12/07/07 471.9% Stansberry's Investment Advisory Porter AFG American Financial 10/12/12 461.5% Stansberry's Investment Advisory Porter TT Trane Technologies 04/12/18 380.5% Retirement Millionaire Doc Please note: Securities appearing in the Top 10 are not necessarily recommended buys at current prices. The list reflects the best-performing positions currently in the model portfolio of any Stansberry Research publication. The buy date reflects when the editor recommended the investment in the listed publication, and the return shows its performance since that date. To learn if a security is still a recommended buy today, you must be a subscriber to that publication and refer to the most recent portfolio. --------------------------------------------------------------- Top 10 Totals 4 Stansberry's Investment Advisory Porter 3 Retirement Millionaire Doc 2 Stansberry Innovations Report Wade 1 Extreme Value Ferris --------------------------------------------------------------- Top 5 Crypto Capital Open Recommendations Top 5 highest-returning open positions in the Crypto Capital model portfolio Stock Buy Date Return Publication Analyst wstETH Wrapped Staked Ethereum 12/07/18 2,291.8% Crypto Capital Wade BTC/USD Bitcoin 11/27/18 1,772.3% Crypto Capital Wade ONE/USD Harmony 12/16/19 1,320.6% Crypto Capital Wade MATIC/USD Polygon 02/25/21 905.3% Crypto Capital Wade AGI/USD Delysium AI 01/16/24 571.3% Crypto Capital Wade Please note: Securities appearing in the Top 5 are not necessarily recommended buys at current prices. The list reflects the best-performing positions currently in the Crypto Capital model portfolio. The buy date reflects when the recommendation was made, and the return shows its performance since that date. To learn if it's still a recommended buy today, you must be a subscriber and refer to the most recent portfolio. --------------------------------------------------------------- Stansberry Research Hall of Fame Top 10 all-time, highest-returning closed positions across all Stansberry portfolios Investment Symbol Duration Gain Publication Analyst Nvidia^* NVDA 5.96 years 1,466% Venture Tech. Lashmet Microsoft^ MSFT 12.74 years 1,185% Retirement Millionaire Doc Band Protocol crypto 0.32 years 1,169% Crypto Capital Wade Terra crypto 0.41 years 1,164% Crypto Capital Wade Inovio Pharma.^ INO 1.01 years 1,139% Venture Tech. Lashmet Seabridge Gold^ SA 4.20 years 995% Sjug Conf. Sjuggerud Frontier crypto 0.08 years 978% Crypto Capital Wade Binance Coin crypto 1.78 years 963% Crypto Capital Wade Nvidia^* NVDA 4.12 years 777% Venture Tech. Lashmet Intellia Therapeutics NTLA 1.95 years 775% Amer. Moonshots Root ^ These gains occurred with a partial position in the respective stocks. * The two partial positions in Nvidia were part of a single recommendation. Editor Dave Lashmet closed the first leg of the position in November 2016 for a gain of about 108%. Then, he closed the second leg in July 2020 for a 777% return. And finally, in May 2022, he booked a 1,466% return on the final leg. Subscribers who followed his advice on Nvidia could've recorded a total weighted average gain of more than 600%. You have received this e-mail as part of your subscription to Stansberry Digest. If you no longer want to receive e-mails from Stansberry Digest [click here](. Published by Stansberry Research. You’re receiving this e-mail at {EMAIL}. Stansberry Research welcomes comments or suggestions at feedback@stansberryresearch.com. This address is for feedback only. For questions about your account or to speak with customer service, call 888-261-2693 (U.S.) or 443-839-0986 (international) Monday-Friday, 9 a.m.-5 p.m. Eastern time. Or e-mail info@stansberryresearch.com. Please note: The law prohibits us from giving personalized financial advice. © 2024 Stansberry Research. All rights reserved. Any reproduction, copying, or redistribution, in whole or in part, is prohibited without written permission from Stansberry Research, 1125 N Charles St, Baltimore, MD 21201 or [stansberryresearch.com](. Any brokers mentioned constitute a partial list of available brokers and is for your information only. Stansberry Research does not recommend or endorse any brokers, dealers, or investment advisors. Stansberry Research forbids its writers from having a financial interest in any security they recommend to our subscribers. All employees of Stansberry Research (and affiliated companies) must wait 24 hours after an investment recommendation is published online – or 72 hours after a direct mail publication is sent – before acting on that recommendation. This work is based on SEC filings, current events, interviews, corporate press releases, and what we've learned as financial journalists. It may contain errors, and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility.